Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1996 2
1997 3
1998 1
2008 1
2015 1
2019 1
2020 1
2021 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Paz-Ares L, et al. Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4. Lancet. 2019. PMID: 31590988 Clinical Trial.
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators. Goldman JW, et al. Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4. Lancet Oncol. 2021. PMID: 33285097 Clinical Trial.
Quality of life after patient-initiated vs physician-initiated response to symptom monitoring: the SYMPRO-Lung trial.
Billingy NE, Tromp VNMF, Aaronson NK, Hoek RJA, Bogaard HJ, Onwuteaka-Philipsen BD, van de Poll-Franse L, Hugtenburg JG, Belderbos J, Becker-Commissaris A, van den Hurk CJG, Walraven I; SYMPRO-Lung Consortium. Billingy NE, et al. J Natl Cancer Inst. 2023 Dec 6;115(12):1515-1525. doi: 10.1093/jnci/djad159. J Natl Cancer Inst. 2023. PMID: 37603720 Free PMC article. Clinical Trial.
Evidence of the in vivo esterification of budesonide in human airways.
van den Brink KI, Boorsma M, Staal-van den Brekel AJ, Edsbäcker S, Wouters EF, Thorsson L. van den Brink KI, et al. Among authors: staal van den brekel aj. Br J Clin Pharmacol. 2008 Jul;66(1):27-35. doi: 10.1111/j.1365-2125.2008.03164.x. Epub 2008 Apr 1. Br J Clin Pharmacol. 2008. PMID: 18384442 Free PMC article. Clinical Trial.
Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer.
Mellema WW, Masen-Poos L, Smit EF, Hendriks LE, Aerts JG, Termeer A, Goosens MJ, Smit HJ, van den Heuvel MM, van der Wekken AJ, Herder GJ, Krouwels FH, Stigt JA, van den Borne BE, Haitjema TJ, Staal-Van den Brekel AJ, van Heemst RC, Pouw E, Dingemans AM. Mellema WW, et al. Among authors: staal van den brekel aj. Lung Cancer. 2015 Nov;90(2):249-54. doi: 10.1016/j.lungcan.2015.09.012. Epub 2015 Sep 15. Lung Cancer. 2015. PMID: 26415993
14 results